Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties
1. BMY's RayzeBio secures exclusive rights for OncoACP3 therapy. 2. Philochem to receive $350m upfront plus up to $1.0bn in milestones. 3. OncoACP3 shows promising early trial results for prostate cancer. 4. This partnership reinforces BMY's position in radiopharmaceuticals. 5. Approval expected in Q3 2025, subject to regulatory requirements.